Journal of Virology · 2015 · 35 citations · 12 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMolecular VirologyVirologyAntiviral Drug ResistanceAntiviral PharmacologyAntiviral ResistanceAntiviral TherapyResistance EvolutionViral MutationAntiviral Resistance MutationsDrug Resistance MutationsIntegrase Inhibitor ResistanceIntegrase Strand Transfer InhibitorsResistance-associated MutationsResistance-associated Viral VariantsReverse Transcriptase Inhibitor ResistanceSubstitutions
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.
12
Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text
Joseph J. Eron, Bonaventura Clotet, J. Durant et al. · The Journal of Infectious Diseases · 2012 · 312 citations · Full text
Peter K. Quashie, Thibault Mésplède, Ying-Shan Han et al. · Journal of Virology · 2011 · 235 citations · Full text
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
Thibault Mésplède, Peter K. Quashie, Nathan Osman et al. · Retrovirology · 2013 · 132 citations · Full text